<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03638219</url>
  </required_header>
  <id_info>
    <org_study_id>Bioscore in breast cancer</org_study_id>
    <nct_id>NCT03638219</nct_id>
  </id_info>
  <brief_title>Prognostic Significance of Bioscore in Nonmetastatic Breast Cancer</brief_title>
  <acronym>Observational</acronym>
  <official_title>Prognostic Significance of Bioscore in Nonmetastatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      assess the validity of applying the bioscore system to predict the disease-free survival (The&#xD;
      percentage of people in a study or treatment group who have not experienced disease relapse&#xD;
      in a defined period of time.) in breast cancer patients presenting to our&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Retrospective cohort analysis of breast cancer patient's records for patients treated with&#xD;
      surgery as an initial intervention at our department from 2015 to 2018 will be identified.&#xD;
      Multivariate analyses of factors, including pathological stage (PS), T stage (T), nodal stage&#xD;
      (N), grade (G), estrogen receptor (ER) status (E) and human epidermal growth factor receptor&#xD;
      (HER2) status will be recorded to identify associations with disease-free survival DFS. A&#xD;
      score of 0-4 will be assigned for each factor by considering the hazard ratio magnitude.&#xD;
&#xD;
      Analysis of the correlation between pathological stage, T stage (T), nodal stage (N), grade&#xD;
      (G), estrogen receptor (ER) status (E) and human epidermal growth factor receptor (HER2)&#xD;
      status combined score and the disease free survival (DFS ).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">October 16, 2020</completion_date>
  <primary_completion_date type="Actual">September 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>the correlation between pathological stage, T stage (T), nodal stage (N), grade (G), estrogen receptor (ER) status (E) and human epidermal growth factor receptor (HER2) status combined score and the disease specific survival (DSS)</measure>
    <time_frame>Non metastatic breast cancer patients presented at our department from 2015 to 2018.. Then follow up till 2020</time_frame>
    <description>Disease free survial:The percentage of people in a study or treatment group who have not experienced disease relapse in a defined period of time. The time period usually begins after surgerical treatment and ends at the end of study period 2020</description>
  </primary_outcome>
  <enrollment type="Actual">317</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data collection about eligible patients presented to our department from 2015 to 2018. Then follow up till 2020.</intervention_name>
    <description>Data collection, follow up and bioscore calculation at the end of study</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        non metastatic breast cancer patients presenting to our department during period of our&#xD;
        study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Female patients Newly diagnosed breast cancer patients presented to clinical oncology&#xD;
        department, Assiut University in the period between (2015_2018).&#xD;
&#xD;
        Histologically confirmed invasive breast carcinoma (IBC) Age: â‰¥18 and older Eastern&#xD;
        Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2. Complete medical records&#xD;
        and follow up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Male patients No definitive surgery Incomplete medical records or follow-up status&#xD;
             Unavailability of hormonal receptor status Carcinoma in situ or other rare tumors of&#xD;
             the breast as phylloides tumors, pregnancy and lactation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Breast cancer in female patients only.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Assiut University hospital</name>
      <address>
        <city>Asyut</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5):E359-86. doi: 10.1002/ijc.29210. Epub 2014 Oct 9.</citation>
    <PMID>25220842</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 16, 2018</study_first_submitted>
  <study_first_submitted_qc>August 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2018</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Donia Hussein Abd Elhamed</investigator_full_name>
    <investigator_title>Principle invistigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

